Centessa Pharmaceuticals (CNTA) FCF Margin (2025)

Centessa Pharmaceuticals (CNTA) reported FCF Margin of 381.64% for Q1 2025.

Centessa Pharmaceuticals (CNTA) FCF Margin (2025) Analysis & Trends

Centessa Pharmaceuticals (CNTA) has 1 years of FCF Margin data on file, last reported at 381.64% in Q1 2025.

  • FCF Margin for Q1 2025 came in at 381.64%, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was 1293.75% (changed N/A YoY), and the FY2025 annual result was 1294.59%, changed N/A from the prior year.
  • FCF Margin was little changed at 381.64% in Q1 2025 per CNTA's latest filing.
  • Over five years, FCF Margin peaked at 381.64% in Q1 2025 and troughed at 381.64% in Q1 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) FCF Margin (Qtr)
1 Alterity Therapeutics 814,307.08 Bn 814,307.05 Bn - -
2 Belite Bio 55,320.00 Bn 55,320.00 Bn - -
3 Quantum Biopharma 17,149.72 Bn 17,149.72 Bn - -
4 Legend Biotech 3,590.00 Bn 3,589.71 Bn 242.10 Mn -3.98%
5 Akari Therapeutics 1,650.72 Bn 1,650.72 Bn - -
6 Evaxion A 1,522.09 Bn 1,522.07 Bn - -
7 Psyence Biomedical 229.39 Bn 229.38 Bn - -
8 Vertex Pharmaceuticals 113.09 Bn 105.85 Bn 2.59 Bn 43.35%
9 Abivax 90.15 Bn 90.15 Bn - -
10 Centessa Pharmaceuticals 6.10 Bn 6.10 Bn - -

Historic Data

Download Data
DateValue
Mar 31, 2025 -381.64%